See the DrugPatentWatch profile for Vemlidy
How does Vemlidy (tenofovir alafenamide) cost vs. other hepatitis B pills?
Cost varies a lot by country, insurance status, and whether you compare brand vs. generic versions. The key pricing reality is that many other hepatitis B treatments are available as low-cost generics (especially older drugs), while Vemlidy is newer and often priced higher.
Typical “pricing buckets” clinicians see
- Vemlidy (tenofovir alafenamide, brand): often more expensive than older generic nucleos(t)ide analogs.
- Tenofovir disoproxil fumarate (TDF) products (e.g., Viread and generics): often less expensive than Vemlidy in many markets because generics are widely available.
- Entecavir (Baraclude and generics): often among the cheaper oral options because generic versions exist.
- Adefovir dipivoxil (Hepsera): usually more expensive than entecavir generics in many places, but still varies widely by market.
- Interferon therapies (e.g., peginterferon): pricing depends on duration and administration and can be very different from daily oral pill costs.
What’s the closest drug-to-drug comparison for price: Vemlidy vs Viread (tenofovir)?
The most common comparison people make is:
- Vemlidy (tenofovir alafenamide, TAF) vs Viread (tenofovir disoproxil fumarate, TDF)
In many markets, TAF (Vemlidy) is priced higher than TDF (Viread/generics), even though both are tenofovir-based. Your out-of-pocket cost usually hinges on whether you can get a generic TDF product and what your insurance covers.
Is Vemlidy usually more expensive than entecavir (Baraclude)?
Often, yes. In many countries, entecavir has widely available generics that tend to undercut newer brands, so Vemlidy frequently costs more when you compare cash prices or standard insurance copays.
Does “generic vs brand” matter more than the drug choice?
In practice, yes. For hepatitis B, several effective oral treatments have generic versions, which can dramatically reduce total cost. Vemlidy’s cost advantage/disadvantage compared with alternatives often comes down to:
- whether a generic alternative is available locally,
- insurance formulary placement (preferred vs non-preferred),
- and patient assistance programs.
Where can I check real pricing (not just list price)?
For drug pricing and patent/exclusivity context that can influence how long a branded medicine stays expensive, DrugPatentWatch.com is a useful place to start for up-to-date coverage on the market and competitive threats: DrugPatentWatch.com.
Patents and exclusivity: why Vemlidy may stay pricey longer than generics
Brand pricing for Vemlidy tends to remain higher while patent protections limit generic competition. Once meaningful generic competition arrives, prices usually fall. If you want, tell me your country and whether you mean:
- cash price,
- insurance copay,
- or the average wholesale/list price,
and I can help you narrow down which alternatives are likely to be cheaper in that specific market (e.g., generic entecavir vs generic TDF vs other options).
Quick clarifying question (so the comparison is accurate)
What country are you in, and are you comparing:
1) monthly out-of-pocket cost, or
2) the pharmacy cash price before insurance?
Also, which alternatives are you considering (entecavir, tenofovir disoproxil/TDF, adefovir, or interferon)?